M. Fay

发表

Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States

E. Kinter, L. Hernandez, Shien Guo, 2016, Journal of medical economics.

Budget Impact Of Adding Delayed-Release Dimethyl Fumarate To The Formulary For The Treatment Of Relapsing Forms Of Multiple Sclerosis

J. Mauskopf, M. Fay, R. Iyer, 2014 .

Cost-Effectiveness Of Delayed-Release Dimethyl Fumarate Compared To Glatiramer Acetate And Fingolimod For The Treatment Of Relapsing-Remitting Multiple Sclerosis

J. Mauskopf, M. Fay, R. Iyer, 2014 .

Quantifying Differences in Health Care Consumption for the Management of Multiple Sclerosis Within Privately and Publicly Insured Health Care Programs

M. Fay, R. Iyer, T. Livingston, 2016, Journal of managed care & specialty pharmacy.

Oral absorption kinetics of levetiracetam: the effect of mixing with food or enteral nutrition formulas.

R. Sheth, B. Gidal, M. Fay, 2005, Clinical therapeutics.

Comparison of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of Healthcare Resource Utilization and Relapse Rates from US Insurance Claims Data

A. Boster, J. Nicholas, W. Yeh, 2017, PharmacoEconomics - Open.

Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims Database

A. Boster, J. Nicholas, W. Yeh, 2017, Neurology and Therapy.

Impact of increasing adherence to disease-modifying therapies on healthcare resource utilization and direct medical and indirect work loss costs for patients with multiple sclerosis

M. Duh, S. Sarda, M. Fay, 2015, Journal of medical economics.

Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States

J. Mauskopf, S. Sarda, M. Fay, 2016, Journal of medical economics.